ProAxsis today announces that the company has appointed Diagenics Limited as the distributor for its ProteaseTag® Active Neutrophil Elastase Immunoassay in Great Britain and Ireland. Founded in 1994, Diagenics supply high quality diagnostic products to NHS and private hospitals, as well as University and industrial biomedical research laboratories throughout the UK region.
Dr David Ribeiro, CEO of ProAxsis, said: “The ProteaseTag® Active NE Immunoassay offers highly sensitive and specific measurement of only the active form of neutrophil elastase. Previously published work has shown that utilising the immunoassay to measure active NE in patients with respiratory disease can help to identify those at greatest risk of an impending pulmonary exacerbation. Due to the increasing interest we’ve received for the immunoassay, we’ve recently sought a commercialisation partner and are delighted to have reached this agreement with Diagenics.”
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact email@example.com or visit www.proaxsis.com
For more information on Diagenics, please visit www.diagenics.co.uk